A new Phase I clinical trial provides proof of concept for a potential therapy for treatment-resistant cancers, particularly kidney cancer. In the new study, published in Cell Reports Medicine, researchers tested a novel kind of immunotherapy in individuals with different types of cancer.
Continue Reading this article here
